ChemicalBook
Chinese Japanese Germany Korea

Levodopa

Levodopa
Levodopa structure
CAS No.
59-92-7
Chemical Name:
Levodopa
Synonyms
Dopar;Parda;l-dop;Doparl;Doprin;Ledopa;Levopa;L-DOPA;Weldopa;Veldopa
CBNumber:
CB2402938
Molecular Formula:
C9H11NO4
Formula Weight:
197.19
MOL File:
59-92-7.mol

Levodopa Properties

Melting point:
276-278 °C(lit.)
alpha 
-11.7 º (c=5.3, 1N HCl)
Boiling point:
334.28°C (rough estimate)
Density 
1.3075 (rough estimate)
refractive index 
-12 ° (C=5, 1mol/L HCl)
storage temp. 
2-8°C
solubility 
Slightly soluble in water, practically insoluble in ethanol (96 per cent). It is freely soluble in 1 M hydrochloric acid and sparingly soluble in 0.1 M hydrochloric acid .
pka
2.32(at 25℃)
form 
Crystalline Powder
color 
White to creamy
Water Solubility 
Slightly soluble in water, dilute hydrochloric acid and formic acid. Insoluble in ethanol.
Merck 
14,5464
BRN 
2215169
Stability:
Stable. Incompatible with strong oxidizing agents. Light and air sensitive.
InChIKey
WTDRDQBEARUVNC-LURJTMIESA-N
CAS DataBase Reference
59-92-7(CAS DataBase Reference)
EWG's Food Scores
1
FDA UNII
46627O600J
NIST Chemistry Reference
Levodopa(59-92-7)
Proposition 65 List
Levodopa
EPA Substance Registry System
Levodopa (59-92-7)
SAFETY
  • Risk and Safety Statements
Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H335
Precautionary statements  P280-P301+P312+P330-P304+P340+P312-P305+P351+P338-P337+P313-P261-P264-P270-P302+P352+P332+P313+P362+P364-P305+P351+P338+P337+P313-P501-P301+P312a-P330-P501a
Hazard Codes  Xn
Risk Statements  22-36/37/38-20/21/22
Safety Statements  26-36-24/25
WGK Germany  3
RTECS  AY5600000
10-23
TSCA  Yes
HS Code  29225090
Toxicity LD50 in mice (mg/kg): 3650 ±327 orally, 1140 ±66 i.p., 450 ±42 i.v., >400 s.c.; in male, female rats (mg/kg): >3000, >3000 orally; 624, 663 i.p.; >1500, >1500 s.c. (Clark)

Levodopa price More Price(17)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich D9628 3,4-Dihydroxy-L-phenylalanine ≥98% (TLC) 59-92-7 5g $55.7 2019-12-02 Buy
Sigma-Aldrich 1361009 Levodopa United States Pharmacopeia (USP) Reference Standard 59-92-7 200mg $352.8 2019-12-02 Buy
TCI Chemical D0600 3-(3,4-Dihydroxyphenyl)-L-alanine >98.0%(HPLC)(T) 59-92-7 5g $31 2020-06-24 Buy
TCI Chemical D0600 3-(3,4-Dihydroxyphenyl)-L-alanine >98.0%(HPLC)(T) 59-92-7 25g $94 2020-06-24 Buy
Alfa Aesar A11311 3,4-Dihydroxy-L-phenylalanine, 98+% 59-92-7 5g $35 2020-06-24 Buy

Levodopa Chemical Properties,Uses,Production

Chemical Properties

Colorless Crystalline Powder

Uses

antiparkinsonian

Uses

An immediate precursor of dopamine and product of tyrosine hydroxylase.

Uses

Natural isomer of the immediate precursor of dopamine; product of tyrsine hydroxylase

Definition

ChEBI: An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease

brand name

Bendopa (Valeant); Dopar (Shire); Larodopa (Roche).

Biological Functions

Levodopa (L-DOPA), the most reliable and effective drug used in the treatment of parkinsonism, can be considered a form of replacement therapy. Levodopa is the biochemical precursor of dopamine. It is used to elevate dopamine levels in the neostriatum of parkinsonian patients. Dopamine itself does not cross the blood-brain barrier and therefore has no CNS effects. However, levodopa, as an amino acid, is transported into the brain by amino acid transport systems, where it is converted to dopamine by the enzyme L-aromatic amino acid decarboxylase.
If levodopa is administered alone, it is extensively metabolized by L-aromatic amino acid decarboxylase in the liver, kidney, and gastrointestinal tract. To prevent this peripheral metabolism, levodopa is coadministered with carbidopa (Sinemet), a peripheral decarboxylase inhibitor. The combination of levodopa with carbidopa lowers the necessary dose of levodopa and reduces peripheral side effects associated with its administration.
Levodopa is widely used for treatment of all types of parkinsonism except those associated with antipsychotic drug therapy. However, as parkinsonism progresses, the duration of benefit from each dose of levodopa may shorten (wearing-off effect). Patients can also develop sudden, unpredictable fluctuations between mobility and immobility (on-off effect). In a matter of minutes, a patient enjoying normal or nearly normal mobility may suddenly develop a severe degree of parkinsonism. These symptoms are likely due to the progression of the disease and the loss of striatal dopamine nerve terminals.

General Description

The first significant breakthrough in the treatment of PDcame about with the introduction of high-dose levodopa.Fahn referred to this as a revolutionary development intreating parkinsonian patients. The rationale for the use oflevodopa for the treatment of PD was established in theearly 1960s. Parkinsonian patients were shown to have decreasedstriatal levels of DA and reduced urinary excretionof DA. Since then, levodopa has shown to be remarkablyeffective for treating the symptoms of PD.Because ofenzymatic action of MAO-A in the gastrointestinal (GI)tract and AADC in the periphery, only a small percentage(1%–2%) of levodopa is delivered into the CNS.Coadministration of levodopa with the AADC inhibitor,carbidopa, prevents decarboxylation of levodopa outside ofthe CNS. The combination of levodopa and carbidopa resultsin a substantial increase in DA delivery to the CNSwith a decrease in peripheral side effects. Long-term therapywith levodopa leads to predictable motor complications.These include loss of efficacy before the next dose(“wearing off”), motor response fluctuations (“on/off”), andunwanted movements (dyskinesias).These effects arethought to be caused by the inability of levodopa therapyto restore normal DA levels in the CNS.As a result, theuse of longer-acting DA agonists may benefit parkinsonianpatients.

Biological Activity

Immediate precursor of dopamine, produced by tyrosine hydroxylase. Displays antiParkinsonian activity.

Safety Profile

Poison by ingestion. Moderately toxic by intravenous and intraperitoneal routes. Human systemic effects by ingestion: somnolence, hallucinations and distorted perceptions, toxic psychosis, motor activity changes, ataxia, dyspnea. Experimental teratogenic and reproductive effects. Questionable human carcinogen producing skin tumors. Human mutation data reported. An anticholinergic agent used as an anti Parhnsonian drug. When heated to decomposition it emits toxic fumes of NOx

Purification Methods

Likely impurities are vanillin, hippuric acid, 3-methoxytyrosine and 3-aminotyrosine. DOPA recrystallises from large volumes of H2O forming colourless white needles; its solubility in H2O is 0.165%, but it is insoluble in EtOH, *C6H6, CHCl3, and EtOAc. Also crystallise it by dissolving it in dilute HCl and adding dilute ammonia to give pH 5, under N2. Alternatively, crystallise it from dilute aqueous EtOH. It is rapidly oxidised in air when moist, and darkens, particularly in alkaline solution. Dry it in vacuo at 70o in the dark, and store it in a dark container preferably under N2. It has at 220.5nm (log 3.79) and 280nm (log 3.42) in 0.001N max HCl. [Yamada et al. Chem Pharm Bull Jpn 10 693 1962, Bretschneider et al. Helv Chim Acta 56 2857 1973, NMR: Jardetzky & Jardetzky J Biol Chem 233 383 1958, Beilstein 4 IV 2492, 2493.]

Levodopa Preparation Products And Raw materials

Raw materials

Preparation Products


Levodopa Suppliers

Global( 436)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Shaanxi Pioneer Biotech Co., Ltd .
86-13259417953(Whatsapp/Wechat) 86-13259417953(Whatsapp)
029-84385017 sales@pioneerbiotech.com CHINA 3001 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30043 58
Casorganics US Corp
+17326109938
sales@casorganics.com CHINA 175 58
Taizhou Tianhong Biochemistry Technology Co., Ltd.
0523-86132544
0523-86201489 sales@thbiochem.com CHINA 306 60
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 22625 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 739 60
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479
025-85710122 sales@fine-chemtech.com CHINA 890 55
Shanghai Zheyan Biotech Co., Ltd.
18017610038
zheyansh@163.com CHINA 3623 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691
yklbiotech@163.com CHINA 297 58

View Lastest Price from Levodopa manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2019-11-26 Levodopa
59-92-7
US $0.00 / mg 5mg ≥98%(HPLC) 10 g Shanghai Standard Technology Co., Ltd.
2020-04-20 Levodopa
59-92-7
US $1.00 / KG 1KG 99% 20T Shaanxi Dideu Medichem Co. Ltd
2018-08-06 Levodopa
59-92-7
US $1.00 / KG 1KG 98% 200KG career henan chemical co

Levodopa Spectrum


59-92-7(Levodopa)Related Search:


Copyright 2017 © ChemicalBook. All rights reserved